Life Science Breakthroughs: June 2026
At ASCO 2026, groundbreaking oncology data revealed Revolution Medicines' daraxonrasib nearly doubled overall survival in pancreatic cancer, while GSK also announced a functional cure for hepatitis B. These significant advancements, alongside Servier's $2.65 billion rare disease deal, mark a transformative period for the life sciences sector across multiple therapeutic areas.